Latest Press Releases
- FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections
- PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients
- Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections
- Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine
- Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing
- Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test
- FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
- Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program
- Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense